Inhaled · GLP-1 agonist
MKC253
2 trials in this molecule. Source: ClinicalTrials.gov, as of July 6, 2026.
Trials
2
Ongoing
0
Recruiting
0
Completed
2
Sites
1
Countries
1
Endpoints
4
Composite endpoints
0
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Where the program stands
Trials by phase
Phase 1
2
Trials by status
Completed
2
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
3
Glycemic / diabetes
1
Top 20 metrics across this asset's endpoints
Postprandial glucoseGlycemic
1
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
2 of 2
| Asset / Population | Eligibility highlight | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT00475371A First in Human, Single Dose, Safety and Tolerability Study of MKC253 Inhalation Powder in Healthy Adult Males | MKC253 Healthy volunteers | BMI ≤30 | Ph 1 | Completed | 1 | Jun 2007 | - | |
| NCT00642538A Study Designed to Determine the Safety and Pharmacological Response ofMKC253 Inhalation Powder in Adults With Type 2 Diabetes Mellitus | Exenatide, MKC253 Type 2 diabetes | BMI ≤32 | Ph 1 | Completed | 1 | Sep 2008 | - |
Showing 1-2 of 2 trials